Trials / Withdrawn
WithdrawnNCT06165809
A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer
A Phase I Study to Evaluate the Safety and Tolerance of TQB3015 Tablets With Advanced Malignant Cancer.
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is divided into two stages: dose escalation and dose extension, including a single dose and a multiple dose clinical study. This is a single-center, open, non randomized, single arm study to the safety and tolerability of TQB3015 tables in patients with advanced malignant cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3015 tablets | TQB3015 is a protein inhibitor |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2024-05-01
- Completion
- 2024-05-01
- First posted
- 2023-12-12
- Last updated
- 2023-12-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06165809. Inclusion in this directory is not an endorsement.